The DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.
Interventions for the management of malignant pleural effusions: a network meta-analysis
Open accessAbstract
BACKGROUND: Malignant pleural effusion (MPE) is a common problem for people with cancer and usually associated with considerable breathlessness. A number of treatment options are available to manage the uncontrolled accumulation of pleural fluid, including administration of a pleurodesis agent (via a chest tube or thoracoscopy) or placement of an indwelling pleural catheter (IPC). This is an update of a review published in Issue 5, 2016, which replaced the original, published in 2004. OBJECTIVES: To ascertain the optimal management strategy for adults with malignant pleural effusion in terms of pleurodesis success and to quantify differences in patient-reported outcomes and adverse effects between interventions. SEARCH METHODS: We searched CENTRAL, MEDLINE (Ovid), Embase (Ovid) and three other databases to June 2019. We screened reference lists from other relevant publications and searched trial registries. SELECTION CRITERIA: We included randomised controlled trials of intrapleural interventions for adults with symptomatic MPE, comparing types of sclerosant, mode of administration and IPC use. DATA COLLECTION AND ANALYSIS: Two review authors independently extracted data on study design, characteristics, outcome measures, potential effect modifiers and risk of bias. The primary outcome was pleurodesis failure rate. Secondary outcomes were adverse events, patient-reported breathlessness control, quality of life, cost, mortality, survival, duration of inpatient stay and patient acceptability. We performed network meta-analyses of primary outcome data and secondary outcomes with enough data. We also performed pair-wise meta-analyses of direct comparison data. If we deemed interventions not jointly randomisable, or we found insufficient available data, we reported results by narrative synthesis. For the primary outcome, we performed sensitivity analyses to explore potential causes of heterogeneity and to evaluate pleurodesis agents administered via a chest tube only. We assessed the certainty of the evidence using GRADE. MAIN RESULTS: We identified 80 randomised trials (18 new), including 5507 participants. We found all except three studies at high or unclear risk of bias for at least one domain. Due to the nature of the interventions, most studies were unblinded. Pleurodesis failure rate We included 55 studies of 21 interventions in the primary network meta-analysis. We estimated the rank of each intervention's effectiveness. Talc slurry (ranked 6, 95% credible interval (Cr-I) 3 to 10) is an effective pleurodesis agent (moderate certainty for comparison with placebo) and may result in fewer pleurodesis failures than bleomycin and doxycycline (bleomycin versus talc slurry: odds ratio (OR) 2.24, 95% Cr-I 1.10 to 4.68; low certainty; ranked 11, 95% Cr-I 7 to 15; doxycycline versus talc slurry: OR 2.51, 95% Cr-I 0.81 to 8.40; low certainty; ranked 12, 95% Cr-I 5 to 18). There is little evidence of a difference between the pleurodesis failure rate of talc poudrage and talc slurry (OR 0.50, 95% Cr-I 0.21 to 1.02; moderate certainty). Evidence for any difference was further reduced when restricting analysis to studies at low risk of bias (defined as maximum one high risk domain in the risk of bias assessment) (pleurodesis failure talc poudrage versus talc slurry: OR 0.78, 95% Cr-I 0.16 to 2.08). IPCs without daily drainage are probably less effective at obtaining a definitive pleurodesis (cessation of pleural fluid drainage facilitating IPC removal) than talc slurry (OR 7.60, 95% Cr-I 2.96 to 20.47; rank = 18/21, 95% Cr-I 13 to 21; moderate certainty). Daily IPC drainage or instillation of talc slurry via IPC are likely to reduce pleurodesis failure rates. Adverse effects Adverse effects were inconsistently reported. We performed network meta-analyses for the risk of procedure-related fever and pain. The evidence for risk of developing fever was of low certainty, but suggested there may be little difference between interventions relative to talc slurry (talc poudrage: OR 0.89, 95% Cr-I 0.11 to 6.67; bleomycin: OR 2.33, 95% Cr-I 0.45 to 12.50; IPCs: OR 0.41, 95% Cr-I 0.00 to 50.00; doxycycline: OR 0.85, 95% Cr-I 0.05 to 14.29). Evidence also suggested there may be little difference between interventions in the risk of developing procedure-related pain, relative to talc slurry (talc poudrage: OR 1.26, 95% Cr-I 0.45 to 6.04; very-low certainty; bleomycin: OR 2.85, 95% Cr-I 0.78 to 11.53; low certainty; IPCs: OR 1.30, 95% Cr-I 0.29 to 5.87; low certainty; doxycycline: OR 3.35, 95% Cr-I 0.64 to 19.72; low certainty). Patient-reported control of breathlessness Pair-wise meta-analysis suggests there is likely no difference in breathlessness control, relative to talc slurry, of talc poudrage ((mean difference (MD) 4.00 mm, 95% CI -6.26 to 14.26) on a 100 mm visual analogue scale for breathlessness; studies = 1; participants = 184; moderate certainty) and IPCs without daily drainage (MD -6.12 mm, 95% CI -16.32 to 4.08; studie
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Graphical tools for network meta-analysis in STATA
Chaimani, A., Higgins, J. P. T., Mavridis, D., Spyridonos, P., & Salanti, G. (2013) · PLoS ONE · doi:10.1371/journal.pone.0076654 · Cited by 2,473
Puhan, M. A., Schunemann, H. J., Murad, M. H., Li, T., Brignardello-Petersen, R., Singh, J. A., Kessels, A. G., Guyatt, G. H., & for the GRADE Working Group (2014) · BMJ · doi:10.1136/bmj.g5630 · Cited by 1,812
Salanti, G. (2012) · Research Synthesis Methods · doi:10.1002/jrsm.1037 · Cited by 1,729
Evaluating the quality of evidence from a network meta-analysis
Salanti, G., Del Giovane, C., Chaimani, A., Caldwell, D. M., & Higgins, J. P. T. (2014) · PLoS ONE · doi:10.1371/journal.pone.0099682 · Cited by 1,402
Jansen, J. P., & Naci, H. (2013) · BMC Medicine · doi:10.1186/1741-7015-11-159 · Cited by 656
Phase III intergroup study of talc poudrage vs talc slurry sclerosis for malignant pleural effusion
Dresler, C. M., Olak, J., Herndon, J. E., Richards, W. G., Scalzetti, E., Fleishman, S. B., Kernstine, K. H., Demmy, T., Jablons, D. M., Kohman, L., et al. (2005) · Chest · doi:10.1378/chest.127.3.909 · Cited by 578
Cited by
Management of Malignant Pleural Effusions. An Official ATS/STS/STR Clinical Practice Guideline
Feller-Kopman, D. J., Reddy, C. B., DeCamp, M. M., Diekemper, R. L., Gould, M. K., Henry, T., Iyer, N. P., Lee, Y. C. G., Lewis, S. Z., Maskell, N. A., et al. (2018) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201807-1415st · Cited by 470
Self-citationMalignant pleural mesothelioma: an update on investigation, diagnosis and treatment
Bibby, A. C., Tsim, S., Kanellakis, N., Ball, H., Talbot, D. C., Blyth, K. G., Maskell, N. A., & Psallidas, I. (2016) · European Respiratory Review · doi:10.1183/16000617.0063-2016 · Cited by 316
Self-citationERS/EACTS statement on the management of malignant pleural effusions
Bibby, A. C., Dorn, P., Psallidas, I., Porcel, J. M., Janssen, J., Froudarakis, M., Subotic, D., Astoul, P., Licht, P., Schmid, R., et al. (2018) · European Respiratory Journal · doi:10.1183/13993003.00349-2018 · Cited by 316
Self-citationOutpatient Talc Administration by Indwelling Pleural Catheter for Malignant Effusion
Bhatnagar, R., Keenan, E. K., Morley, A. J., Kahan, B. C., Stanton, A. E., Haris, M., Harrison, R. N., Mustafa, R. A., Bishop, L. J., Ahmed, L., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1716883 · Cited by 279
Self-citation
Metadata
- Authors
- Clive, A. O., Jones, H. E., Bhatnagar, R., Preston, N. J., & Maskell, N.
- Venue
- Cochrane Database of Systematic Reviews
- Publisher
- Wiley
- Published
- 2016-05-08
- Volume
- 4
- Issue
- 5
- Pages
- CD010529-CD010529
- ISSN
- 1361-6137 (ISSN-L)
- 1465-1858
- OpenAlex
- W2346044936
- Cited by
- 228
- References
- 6
- FWCI
- 21.45
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Interventions for the management of malignant pleural effusions: a network meta-analysis. https://app.cochat.ai/papers/10.1002/14651858.cd010529.pub2
- The paper
- Clive, A. O., Jones, H. E., Bhatnagar, R., Preston, N. J., & Maskell, N. (2016). Interventions for the management of malignant pleural effusions: a network meta-analysis. Cochrane Database of Systematic Reviews. https://doi.org/10.1002/14651858.cd010529.pub2
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.